The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Department of Radiology, The First Hospital of Lanzhou University, Lanzhou, China.
Clin Hemorheol Microcirc. 2024;88(2):171-180. doi: 10.3233/CH-242286.
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, accounting for approximately 90% of liver cancer cases. It currently ranks as the fifth most prevalent cancer worldwide and represents the third leading cause of cancer-related mortality. As a malignant disease with surgical resection and ablative therapy being the sole curative options available, it is disheartening that most HCC patients who undergo liver resection experience relapse within five years. Microvascular invasion (MVI), defined as the presence of micrometastatic HCC emboli within liver vessels, serves as an important histopathological feature and indicative factor for both disease-free survival and overall survival in HCC patients. Therefore, achieving accurate preoperative noninvasive prediction of MVI holds vital significance in selecting appropriate clinical treatments and improving patient prognosis. Currently, there are no universally recognized criteria for preoperative diagnosis of MVI in clinical practice. Consequently, extensive research efforts have been directed towards preoperative imaging prediction of MVI to address this problem and the relative research progresses were reviewed in this article to summarize its current limitations and future research prospects.
肝细胞癌(HCC)是原发性肝癌的主要形式,约占肝癌病例的 90%。它目前是全球第五大常见癌症,也是癌症相关死亡的第三大主要原因。作为一种恶性疾病,手术切除和消融治疗是唯一的治愈方法,但令人沮丧的是,大多数接受肝切除术的 HCC 患者在五年内复发。微血管侵犯(MVI)定义为肝内血管中存在微小转移性 HCC 栓塞,是 HCC 患者无病生存率和总生存率的重要组织病理学特征和预后因素。因此,准确预测 MVI 的术前非侵入性诊断对于选择合适的临床治疗方法和改善患者预后具有重要意义。目前,临床实践中尚无公认的 MVI 术前诊断标准。因此,人们进行了广泛的研究,以通过术前影像学预测 MVI 来解决这个问题,本文综述了相关的研究进展,以总结其当前的局限性和未来的研究前景。